Phase I rectally-formulated rectal microbicide

I期直肠配制直肠杀菌剂

基本信息

项目摘要

Receptive anal intercourse (AI) is a common practice among heterosexuals with rates from 5-10% in the general population of women up to 30-50% among women with other risk for HIV infection, both in the US and abroad. AI is considered to be the most common route of HIV transmission in men who have sex with men (MSM). Because of this broad and continuing HIV risk, topical HIV rectal microbicides are being developed to prevent rectal sexual transmission of HIV. The overall MDP proposal addresses the need to define the optimal means of developing rectal microbicides for the prevention of HIV transmission associated with anal intercourse (AI). Assessments of safety and efficacy for rectal microbicides must consider that rectal intercourse itself may induce mucosal inflammation, negatively conditioning the environment in which the microbicides will be tested as well as confounding the safety indices by which a drug candidate would be evaluated. We hypothesize that the mechanical trauma of AI damages the mucosa with subsequent inflammatory changes which both enhance the risk for HIV infection in the seronegative host and increase HIV shedding in the seropositive host. Failure to adjust for these modifiers of safety and efficacy may result in both (i) falsely attributing AI toxicity to the microbicide and (ii) failing to demonstrate efficacy because of simultaneous enhancement of HIV infection due to AI. To characterize the immuno-inflammatory consequences of AI on the rectal mucosa, we propose to simulate AI in clinical studies. In escalating dose-response studies, we will (1) reproducibly expose the rectal mucosa to increasing degrees of coital stress through the use of simulated AI, based on behaviorally relevant conditions. Comparing results from partnered couples in a similarly designed trial will (2) validate the results from the simulated model, and support its use in future studies. To support these studies, we will also (3) define the temporal evolution of the mucosal response to mechanical (AI) and chemical (Nonoxynol-9) trauma and (4) define performance characteristics of novel rectal permeability measurements.
接受性肛交(AI)是异性恋者中的一种常见做法,其发生率一般在5%-10%之间 在美国和国外,有其他艾滋病毒感染风险的妇女中,妇女比例高达30%-50%。AI是 被认为是男男性行为者(MSM)中最常见的艾滋病毒传播途径。由于这种广泛和持续的艾滋病毒风险,正在开发局部艾滋病毒直肠杀菌剂来防止直肠性行为。 艾滋病毒的传播。总的MDP提案涉及需要确定开发直肠杀菌剂的最佳手段,以防止与肛交(AI)相关的艾滋病毒传播。对直肠杀微生物剂的安全性和有效性的评估必须考虑到,直肠性交本身可能会引起粘膜炎症,对测试杀菌剂的环境产生负面影响,并混淆了评估候选药物的安全指数。我们假设AI的机械创伤损害了粘膜,并伴随着随后的炎症变化,这些变化既增加了血清阴性宿主中艾滋病毒感染的风险,又增加了血清阳性宿主中艾滋病毒的脱落。如果不对这些安全性和有效性的修饰物进行调整,可能会导致(I)错误地将AI毒性归因于杀菌剂,以及(Ii)由于AI同时增强艾滋病毒感染而未能证明有效性。为了表征AI对直肠黏膜的免疫炎症后果,我们建议在临床研究中模拟AI。在不断升级的剂量-反应研究中,我们将(1)基于行为相关条件,通过使用模拟人工智能,重复地将直肠粘膜暴露于不断增加的性行为应激程度。在类似设计的试验中比较伴侣伴侣的结果将(2)验证模拟模型的结果,并支持它在未来的研究中使用。为了支持这些研究,我们还将(3)定义机械创伤(AI)和化学创伤(Nonoxnol-9)对粘膜反应的时间演变,以及(4)定义新的直肠通透性测量的性能特征。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Craig Walter Hendrix其他文献

Craig Walter Hendrix的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Craig Walter Hendrix', 18)}}的其他基金

Phosphorylation of Drugs in Colonic Tissue
结肠组织中药物的磷酸化
  • 批准号:
    10653625
  • 财政年份:
    2022
  • 资助金额:
    $ 58.28万
  • 项目类别:
Population Pharmacokinetic Modeling and Clinical Trial Simulation to optimize HIV Prevention in Pregnancy and Postpartum
群体药代动力学模型和临床试验模拟可优化妊娠期和产后的艾滋病毒预防
  • 批准号:
    10316144
  • 财政年份:
    2021
  • 资助金额:
    $ 58.28万
  • 项目类别:
Development of Rectal Enema As Microbicide (DREAM)
直肠灌肠剂作为杀菌剂的开发(DREAM)
  • 批准号:
    9088326
  • 财政年份:
    2014
  • 资助金额:
    $ 58.28万
  • 项目类别:
Exploratory Pharmcokinetics of UC781 & Tenofovir Vaginal Microbicide Gel V Film
UC781 的探索性药代动力学
  • 批准号:
    8660270
  • 财政年份:
    2014
  • 资助金额:
    $ 58.28万
  • 项目类别:
Clinical optimization of a tenofovir enema and adherence tracking
替诺福韦灌肠和依从性跟踪的临床优化
  • 批准号:
    8768695
  • 财政年份:
    2014
  • 资助金额:
    $ 58.28万
  • 项目类别:
Exploratory Pharmcokinetics of UC781 & Tenofovir Vaginal Microbicide Gel V Film
UC781 的探索性药代动力学
  • 批准号:
    8471644
  • 财政年份:
    2013
  • 资助金额:
    $ 58.28万
  • 项目类别:
The effect of Depo-Provera on HIV susceptibility, immune activation, and PrEP PK
Depo-Provera 对 HIV 易感性、免疫激活和 PrEP PK 的影响
  • 批准号:
    8588047
  • 财政年份:
    2013
  • 资助金额:
    $ 58.28万
  • 项目类别:
Clinical Laboratory & Biomarker Core
临床实验室
  • 批准号:
    10458362
  • 财政年份:
    2012
  • 资助金额:
    $ 58.28万
  • 项目类别:
Pre-Phase I Evaluations
第一阶段前期评估
  • 批准号:
    8404840
  • 财政年份:
    2012
  • 资助金额:
    $ 58.28万
  • 项目类别:
Clinical Laboratory & Biomarker Core
临床实验室
  • 批准号:
    10612986
  • 财政年份:
    2012
  • 资助金额:
    $ 58.28万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 58.28万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 58.28万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 58.28万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 58.28万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 58.28万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 58.28万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 58.28万
  • 项目类别:
    EU-Funded
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 58.28万
  • 项目类别:
    Standard Grant
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 58.28万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 58.28万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了